A A A

Camargo - DIA 2010 Print
Wednesday, 30 June 2010
Ken Phelps, President and CEO of Camargo, attends DIA 2010 and explains the company's expertise in the use of the 505(b)(2) Pathway. With new FDA changes to device legislation and big pharma companies embarking on biosimilars and biologics, Camargo's customers including some of the largest generics companies, can look to reevaluate their business model and look in to 505(b)(2) as an optional way to bring drugs to marketplace.
 

sign up for email newsletters
Privacy Policy
Copyright © 1996-2010, Jameson Publishing, Inc.